Please login to the form below

Not currently logged in
Email:
Password:

Arterial

This page shows the latest Arterial news and features for those working in and with pharma, biotech and healthcare.

J&J earnings top expectations, but feels the squeeze in US

J&J earnings top expectations, but feels the squeeze in US

This includes cardiovascular blockbuster Xarelto, which saw a 14.4% decline, despite the FDA approving a new 2.5mg dose for those with chronic coronary or peripheral arterial disease (CAD/PAD).

Latest news

More from news
Approximately 5 fully matching, plus 85 partially matching documents found.

Latest Intelligence

  • Is it time we stopped talking about adherence? Is it time we stopped talking about adherence?

    The EarthWorks has employed this philosophy to develop award-winning patient support programmes in chronic conditions such as asthma and HIV, and rare, complex conditions such as pulmonary arterial hypertension.

  • Mobile health and patient outcomes Mobile health and patient outcomes

    diabetes patients to remember their nutritional plan when in a supermarket or advising patients with pulmonary arterial hypertension that their average six-minute walking distance has decreased, prompting them to speak

  • The three forces behind the re-imagining of patient care The three forces behind the re-imagining of patient care

    Using apps to manage chronic conditions such as diabetes and asthma and rare disease such as pulmonary arterial hypertension can now be proven to improve clinical care.

  • Pharma deals in September 2015 Pharma deals in September 2015

    In an attempt to be hunter rather than hunted, and to diversify its portfolio from just PAH (pulmonary arterial hypertension), Actelion has acknowledged it is holding “preliminary discussions with ZS Pharma”.

  • Deal Watch table for June 2013 Deal Watch table for June 2013

    75. Taiwan Liposome Company / SciClone Pharmaceuticals. Exclusive licence. Commercialisation of ProFlow (lipid emulsion-based formulation of alprostadil) for peripheral arterial disease (approved Taiwan).

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

  • Former Novartis vaccines CMO joins Arterial Former Novartis vaccines CMO joins Arterial

    Dr Markus Weissbach becomes clinical trials director. Arterial Capital Management, a life science-focused private equity firm, has appointed Dr Markus Weissbach as clinical trials director and a member of its ... David Evans, director of Arterial, said:

  • Kite Pharma appoints Zelboraf scientist as CMO Kite Pharma appoints Zelboraf scientist as CMO

    Prior to joining Plexxikon, Dr Nolop was VP of clinical research at CoTherix, where he led the development and US approval for Ventavis (iloprost) to treat pulmonary arterial hypertension (PAH).

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fendix

Fendix is the only NHS digital media network and it provides organisations, such as pharma, with unrivalled digital access to...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics